American Journal of Clinical Dermatology

, Volume 15, Issue 4, pp 339–356

Optimal Management of Skin Cancer in Immunosuppressed Patients


  • Lauren Brin
    • Creighton University School of Medicine
  • Adeel S. Zubair
    • Mayo Medical School, Mayo Clinic
    • Division of Dermatologic Surgery, Department of DermatologyMayo Clinic/Mayo Clinic College of Medicine
Review Article

DOI: 10.1007/s40257-014-0085-5

Cite this article as:
Brin, L., Zubair, A.S. & Brewer, J.D. Am J Clin Dermatol (2014) 15: 339. doi:10.1007/s40257-014-0085-5


Skin cancer is the most common malignancy in humans with basal cell carcinoma representing the majority of cases in the general population. The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukemia or those with iatrogenic immunosuppression following organ transplantation. In addition, these patients experience greater morbidity and mortality associated with skin cancers. The most common skin cancer in immunosuppressed patients is squamous cell carcinoma, which often presents with more aggressive features and has a greater rate of metastasis. This article reviews the risk factors, etiology, clinical presentation, and prevalence of skin cancer amongst immunosuppressed patients, including organ transplant, lymphoproliferative disorders, autoimmune disorders, and human immunodeficiency virus. We also provide a comprehensive review of treatment guidelines for immunosuppressed patients with cutaneous malignancy. Surgical therapy is the cornerstone of treatment; however, we also discuss pharmacologic treatment options, lifestyle modifications, and revision of immunosuppressive regimens.

Copyright information

© Springer International Publishing Switzerland 2014